Although the clinical trials industry is rapidly adopting real-world data (RWD), significant barriers and challenges remain to accessing robust, primary patient data, which impacts the optimal use of real-world evidence (RWE), according to a new survey by Inteliquet of professionals from pharma, biopharma, medical technology, and medical device companies, as well as contract research organizations.